Efficacy

• More than 600,000 prescriptions for Carac® written since launch[4]

  Percent of patients with complete clearance of AK lesions[5]* Percent of patients with 75% clearance of AK lesions[5]* * Results from 2 vehicle-controlled, randomized, double-blind, multicenter studies consisting of 384 adult male and female patients with actinic keratoses. In both studies, treatment with Carac® Cream is compared to treatment with vehicle cream. Outcomes from treatment with vehicle cream are pooled because duration of treatment with vehicle had no substantive effect on clearance.[5]

• Carac® demonstrated complete AK lesion clearance in up to 4 weeks of treatment, as tolerated[5]

• Carac® provides complete AK clearance with the added value of once-a-day dosing[5]

  Mean percent reductions in AK lesion counts[6-8]* * Percent reduction based on least squares means of integrated results from 2 vehicle-controlled, randomized, double-blind, multicenter studies consisting of 384 adult male and female patients with actinic keratoses.[6-8]

• Carac® provides >90% reduction in the number of AK lesions after 4 weeks of treatment[6-8]

• In clinical studies, treatment with Carac® for 1, 2, and 4 weeks resulted in significantly greater lesion reduction than with vehicle (P<0.001)[6-8]

• Carac® is the only topical 5-FU with the added value of convenient once-a-day dosing